PriceTargets.com logo

Impax Laboratories - IPXL Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.30 As of 05/4/2018 01:00 AM ET
+0 (0.00%)
Get New Impax Laboratories Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IPXL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IPXL

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Impax Laboratories in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.30.

This chart shows the closing price for IPXL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Impax Laboratories. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2018BarclaysInitiated CoverageOverweight ➝ Overweight$27.00High
4/16/2018BMO Capital MarketsBoost TargetMarket Perform ➝ Market Perform$18.00 ➝ $20.00High
3/7/2018SunTrust BanksInitiated CoverageBuy ➝ Buy$24.00High
3/2/2018Royal Bank of CanadaSet TargetHold$20.00Low
3/1/2018CowenSet TargetHold$21.00Medium
3/1/2018Cantor FitzgeraldSet TargetBuy$35.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Impax Laboratories logo
Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.
Read More

Today's Range

Now: $18.30
Low: $17.40
High: $18.95

50 Day Range

MA: $18.30
Low: $18.30
High: $18.30

52 Week Range

Now: $18.30
Low: $13.05
High: $25.70

Volume

3,041,017 shs

Average Volume

945,265 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Impax Laboratories?

The following Wall Street sell-side analysts have issued reports on Impax Laboratories in the last twelve months:
View the latest analyst ratings for IPXL.

What is the current price target for Impax Laboratories?

0 Wall Street analysts have set twelve-month price targets for Impax Laboratories in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Impax Laboratories in the next year.
View the latest price targets for IPXL.

What is the current consensus analyst rating for Impax Laboratories?

Impax Laboratories currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IPXL.

What other companies compete with Impax Laboratories?

Other companies that are similar to Impax Laboratories include Aclarion, Ainos, Alopexx, Alpha Tau Medical and Alvotech. Learn More about companies similar to Impax Laboratories.

How do I contact Impax Laboratories' investor relations team?

Impax Laboratories' physical mailing address is 30831 HUNTWOOD AVENUE, HAYWARD CA, 94544. The specialty pharmaceutical company's listed phone number is (908) 947-3120 and its investor relations email address is [email protected] The official website for Impax Laboratories is www.impaxlabs.com. Learn More about contacing Impax Laboratories investor relations.